Publication: p53 mutation and protein alteration in 50 gliomas. Retrospective study by DNA-sequencing techniques and immunohistochemistry
Loading...
Date
1997
Authors
von Eckardstein, K. ; Gries, H. ; Bolik, E. ; Cervós-Navarro, J. ; Tschairkin, I.N. ; Patt, Stephan
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Alterations of the p53 protein, which is a 53
kD phosphoprotein and gene product of the p53 gene,
has been found to play a major role in the genesis of a
variety of human malignancies including tumors of the
central nervous system.
We investigated 50 tumor specimens from primary
central nervous system neoplasms. Tissue samples were
screened for mutations by the single-strand conformation
polymorphism method and detected mutations were
sequenced. Al1 tissue specimens were stained immuno- '
histochemically for p53 protein, which when altered
accumulates in the nucleus due to prolonged halflife.
Mutations were found in six cases, including one
pilocytic astrocytoma World Health Organisation
(WHO) grade 1, two astrocytomas WHO grade 11, two
anaplastic astrocytomas WHO grade 111, and one
primitive neuroectodermal tumor (PNET). In terms of
relative frequency mutations were found mostly in the
group of anaplastic astrocytomas WHO grade 111.
Interestingly, no mutations were found in the group of
investigated glioblastomas. P53 immunopositivity did
not correlate with the mutations found, whereas the
staining index was significantly higher in the cases with
detected mutations than in those without.
When p53 alteration is seen as an indicator for
different pathogenic pathways in glioma formation, this
study gives evidence for a difference between anaplastic
astrocytoma and glioblastoma. However, since there was
a great overlap in p53 immunopositivity and p53
mutation in tumors of different WHO grades and
entities, it seems that p53 will not act as a marker
molecule neither for tumor entities nor for tumor
malignancy.
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.